TWI309647B - - Google Patents

Download PDF

Info

Publication number
TWI309647B
TWI309647B TW091102988A TW91102988A TWI309647B TW I309647 B TWI309647 B TW I309647B TW 091102988 A TW091102988 A TW 091102988A TW 91102988 A TW91102988 A TW 91102988A TW I309647 B TWI309647 B TW I309647B
Authority
TW
Taiwan
Prior art keywords
group
hydrogen atom
alkyl
alkoxy
substituted
Prior art date
Application number
TW091102988A
Other languages
English (en)
Chinese (zh)
Inventor
Kawahara Eiji
Takeshi Suzuki
Abe Daisuke
Nakajou Masahiro
Naoko Ueda
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of TWI309647B publication Critical patent/TWI309647B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW091102988A 2001-02-21 2002-02-21 TWI309647B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001045827 2001-02-21
JP2001353525 2001-11-19

Publications (1)

Publication Number Publication Date
TWI309647B true TWI309647B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-05-11

Family

ID=26609852

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091102988A TWI309647B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-02-21 2002-02-21

Country Status (10)

Country Link
US (2) US7294629B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1369418B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4285996B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100861486B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1264824C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE475652T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2442742A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60237145D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI309647B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2002066445A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
HRP20080329T3 (en) 2003-09-16 2008-08-31 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
PT1667992E (pt) * 2003-09-19 2007-04-30 Astrazeneca Ab Derivados de quinazolina
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
JP2007506716A (ja) * 2003-09-25 2007-03-22 アストラゼネカ アクチボラグ キナゾリン誘導体
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CA2545711A1 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
EP1690856A4 (en) * 2003-11-28 2007-09-05 Aveo Pharmaceuticals Inc CHINAZOLINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF
WO2005075439A1 (en) 2004-02-03 2005-08-18 Astrazeneca Ab Quinazoline derivatives
RS52119B (en) 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-phenylamino-HINAZOLIN-6-IL-STARCHES
US20080200433A1 (en) * 2004-09-01 2008-08-21 Tsuyoshi Suzuki Molecular Chaperone Function Regulator
CN101124228B (zh) 2004-12-14 2011-06-15 阿斯利康(瑞典)有限公司 用作抗肿瘤药物的吡唑并嘧啶化合物
US8202879B2 (en) 2005-02-23 2012-06-19 Shionogi & Co., Ltd. Quinazoline derivatives having tyrosine kinase inhibitory activity
MX2007010399A (es) 2005-02-26 2007-09-25 Astrazeneca Ab Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina.
WO2006106721A1 (ja) * 2005-03-30 2006-10-12 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するピリミジン誘導体
JP2009508918A (ja) 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物
EP2010183A4 (en) * 2006-03-03 2010-08-25 Aveo Pharmaceuticals Inc PROCESS FOR SYNTHESIS OF 7-ALKINYL-4-AMINOCHINAZOLINES AND A RELATED INTERMEDIATE COMPOUND
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
DK2245026T3 (da) 2008-02-07 2012-10-15 Boehringer Ingelheim Int Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
EA019183B1 (ru) * 2008-05-13 2014-01-30 Астразенека Аб Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
MX2012010557A (es) * 2010-03-16 2012-10-05 Merck Patent Gmbh Morfolinilquinazolinas.
KR20220031732A (ko) * 2011-03-04 2022-03-11 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CA2861010A1 (en) 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
CN103254143B (zh) * 2013-04-26 2015-10-07 浙江工业大学 4-[4-(2-二乙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用
CN104119350B (zh) 2013-04-28 2017-04-12 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
CN105916851A (zh) 2013-07-11 2016-08-31 艾森生物科学公司 嘧啶衍生物作为激酶抑制剂
AU2016334141B2 (en) 2015-10-09 2019-12-19 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN110430881A (zh) * 2017-01-30 2019-11-08 盐野义制药株式会社 含有喹唑啉衍生物的固体制剂
CN111212837A (zh) 2017-04-07 2020-05-29 艾森医药公司 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
US20220298120A1 (en) * 2019-08-15 2022-09-22 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134236B2 (ja) 1992-01-30 2001-02-13 株式会社林原生物化学研究所 α−グリコシル−L−アスコルビン酸高含有物の製造方法とその製造のための分離システム
JP2994165B2 (ja) 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GEP20012442B (en) 1996-04-12 2001-05-25 Warner Lambert Co Irreversible Inhibitors of Tyrosine Kinases
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
UA73990C2 (en) * 2000-06-22 2005-10-17 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cells growth
EP1690856A4 (en) * 2003-11-28 2007-09-05 Aveo Pharmaceuticals Inc CHINAZOLINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
CA2442742A1 (en) 2002-08-29
JP4285996B2 (ja) 2009-06-24
EP1369418A4 (en) 2005-09-14
US20040116422A1 (en) 2004-06-17
KR100861486B1 (ko) 2008-10-02
EP1369418A1 (en) 2003-12-10
US7294629B2 (en) 2007-11-13
DE60237145D1 (de) 2010-09-09
EP1369418B1 (en) 2010-07-28
CN1264824C (zh) 2006-07-19
US20070265260A1 (en) 2007-11-15
ATE475652T1 (de) 2010-08-15
KR20030086269A (ko) 2003-11-07
JPWO2002066445A1 (ja) 2004-06-17
WO2002066445A1 (fr) 2002-08-29
CN1492860A (zh) 2004-04-28

Similar Documents

Publication Publication Date Title
TWI309647B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN112105610A (zh) 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
JP6457623B2 (ja) 2,4−二置換7H−ピロロ[2,3−d]ピリミジン誘導体、その製造方法および医薬における使用
TWI250152B (en) N,N-substituted cyclic amine compounds used as calcium antagonizer
CN112585119A (zh) 经取代的吲哚及其使用方法
TWI555742B (zh) 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, The use of medicine
WO2001083456A1 (fr) Derives d'heteroaryle condenses
KR20120051702A (ko) N-〔3-플루오로-4-({6-(메틸옥시)-7-〔(3-모르폴린-4-일프로필)옥시〕퀴놀린-4-일}옥시)페닐〕-n''-(4-플루오로페닐)시클로프로판-1,1-디카르복사미드의 결정형
CN113717156A (zh) Egfr抑制剂、其制备方法及用途
TW200914443A (en) Process for preparing substituted quinazolinyl furanaldehyde
WO2023198191A1 (zh) 一种六元并六元化合物、制备方法、药物组合物和应用
CN105254615A (zh) 苯胺嘧啶衍生物及其在制备抗恶性肿瘤药物中的用途
CN109863137A (zh) Lsd1抑制剂及其医学用途
CN101638383B (zh) 喹啉衍生物及其药物组合物和用途
CN107698603A (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
WO2014055938A1 (en) Novel compounds, their preparation and their uses
CN117203199A (zh) N2-苯基嘧啶-2,4-二胺化合物及其制备方法和使用方法
CN116490201A (zh) Yap/taz-tead肿瘤蛋白的抑制剂,其合成和用途
JP2022515890A (ja) エストロゲン受容体タンパク質分解薬
TW200922558A (en) Indazole acrylic and amide compound
WO2024026423A1 (en) Substituted quinoline derivatives as pi3k inhibitors
TWI780077B (zh) 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用
CN103936762B (zh) 吗啉并喹啉类化合物,其制备方法和用途
JP2020526593A (ja) N−フェニル−2−アミノピリミジン類化合物の結晶形、塩形態及びその製造方法
JP6294561B2 (ja) 多置換ピリジン化合物、調製方法、用途、および医薬組成物